Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma announced positive clinical data from a Phase Ib study combining its core drug olverembatinib with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) and Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL). The combination showed high response rates and man…